Pipeline: Vitiligo

EXPLORING POTENTIAL APPLICATION IN VITILIGO

Vitiligo is a disease affecting approximately 6.5 million people in the U.S. resulting in loss of color, or pigmentation, in patches of skin that impacts the quality of life for those living with the condition. [1], [2]

Ongoing research with the RECELL® System for the treatment of skin defects, such as vitiligo and dermatological diseases, help share experiences among the medical community. Below is a case study provided as background. For general information about our science and technology, please contact our Medical Affairs team.

CASE STUDY: STABLE VITILIGO

Researchers conducted a randomized controlled pilot study utilizing Spay-On Skin™ Cells for the treatment of stable vitiligo and piebaldism patients. The image below shows two recipients sites before and 6 months after treatment.

RECELL treated vitiligo patient

AT 6 MONTHS
RECELL®-TREATED AREA WAS 100% REPIGMENTED


ADDITIONAL RESEARCH: Abstracts, Posters, Presentations

  • Ren et al. J Cosmet Deratol. The use of noncultured regenerative epithelial suspension for improving skin color and scars: A report of 8 cases and review of the literature. 2019 Jul 26.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13071
  • Poster: L Wei Wei. Is suction blister epidermal grafting a simple and reliable way to screen patients with large area vitiligo for ReCell treatment? 2019 June 10-15; World Congress of Dermatology; Milan, Italy.
  • Poster: L Zhifei. Spontaneous pigmentation spots are signs of successful ReCell therapy in patients with stable large area vitiligo. 2019 June 10-15; World Congress of Dermatology; Milan, Italy.
  • Poster: Y Nu. Is suction blister epidermal grafting a simple and reliable way to screen patients with large area vitiligo for ReCell treatment? 2019 June 10-15; World Congress of Dermatology; Milan, Italy.
  • Presentation. L Fei. Repigmentation with RECELL technology and dermabrasion in stable Vitiligo. 2019 September 9; National Academic Exchange Conference of the Chinese Medical Association Plastic Surgery Branch of the Chinese Academy of Medical Sciences and Plastic Surgery; Beijing, China.
  • Presentation. L Zhifei. Repigmentation with RECELL technology and dermabrasion in stable Vitiligo. 2019 September 9; 8th Chinese Annual Meeting, Minimally Invasive Aesthetic Medicine; China.
  • Presentation. Uitentuis. Autologous cell suspension transplantation concurrent with UVB in non-segmental vitiligo patients: a randomized controlled study. 2020 July 18-20; IPCC Japan; Yamagata, Japan.
  • Komen et. al. J Am Acad Dermatol. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study. 2015 Jul;73(1):170-2
    https://pubmed.ncbi.nlm.nih.gov/26089056/
  • Cervelli et al. Acta Dernatovenerol Croat. Treatment of stable vitiligo by RECELL® System. 2009;17(4):273-278.
    https://pubmed.ncbi.nlm.nih.gov/20021980/
  • Cervelli et al. European Review for Medical and Pharmacological Sciences. Treatment of stable vitiligo hands by RECELL® system: a preliminary report. 2010;14(8):691-4
    https://pubmed.ncbi.nlm.nih.gov/20707289/
  • Lommerts et. al. BJ Dermatol. Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO2 laser recipient-site preparations. 2017;177:1293-1298.
    https://pubmed.ncbi.nlm.nih.gov/28403523/
  • Mulekar et. al. Br J Dermatol. Treatment of vitiligo lesions by RECELL® vs conventional melanocyte keratinocyte transplantation: a pilot study. 2008 Jan;158(1):45-9
    https://pubmed.ncbi.nlm.nih.gov/17927795/
  • Komen et al. J Cutan Aesthet Surg. Observations on CO2 laser preparation of recipient site for noncultured cell suspension transplantation in vitiligo. 2016 Apr-Jun;9(2):133-5. doi: 10.4103/0974-2077.184055
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924413/
  • Liu et al. J Dermatolog Treat. The clinical efficacy of treatment using the autologous non-cultured epidermal cell suspension technique for stable vitiligo in 41 patients. 2019 May 31:1-5.
    https://pubmed.ncbi.nlm.nih.gov/31084382/

CAUTION:  The use of RECELL® as a treatment of stable vitiligo lesions is limited by U.S. law to investigational use.

The RECELL® System is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute thermal burns in patients 18 years and older. Click here for Important Safety Information and Instructions for Use.


  1. Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017
  2. Willingness-to-pay and quality of life in patients with vitiligo. Radtke, et al. BJD. 2009
This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.